Inflammatory mediators and pathways

Inflammatory mediators and pathways refer to a complex network of signaling molecules and biochemical routes that coordinate the body's response to harmful stimuli, such as pathogens, damaged cells, or irritants (StatPearls, 2023). This category is not a single therapeutic target but rather encompasses a wide array of specific molecules, including cytokines (e.g., TNF, IL-1, IL-6), chemokines, lipid mediators (e.g., prostaglandins, leukotrienes), and intracellular signaling cascades like the NF-kappaB and JAK-STAT pathways (NIH, 2022). While acute inflammation is a protective mechanism essential for healing, chronic dysregulation of these pathways is a central driver in numerous pathologies, including rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis (PubMed, 2021). Therapeutic intervention typically involves highly specific agents designed to inhibit individual components of these pathways, such as monoclonal antibodies against cytokines or small molecule inhibitors of enzymes and kinases (Nature Reviews Drug Discovery, 2020). Because these pathways are integral to normal immune surveillance and homeostasis, pharmacological modulation often carries significant risks of immunosuppression and increased infection rates.

Other names

Inflammatory signalingPro-inflammatory mediatorsInflammatory cascadeInflammatory response

Drugs targeting these pathways act through various mechanisms, including the inhibition of pro-inflammatory enzymes (e.g., COX-2), neutralization of circulating cytokines (e.g., TNF-alpha, IL-6), blockade of cytokine receptors, or inhibition of intracellular signaling kinases (e.g., JAK).